2. Signaling Pathways
  3. Immunology/Inflammation
  4. CD28
  5. CD28 Agonist

CD28 Agonist

CD28 Agonists (3):

Cat. No. Product Name Effect Purity
  • HY-P9975
    Theralizumab
    		Agonist 99.46%
    Theralizumab (TGN1412) is a humanized lgG4 superagonistic anti-CD28 monoclonal antibody that directly stimulates T cells. Theralizumab can cause cytokine release syndrome (CRS). Theralizumab can be used for the research of rheumatoid arthritis.
  • HY-P991176
    RG-6333
    		Agonist 98.05%
    RG-6333 is a bispecific agonist targeting CD19 and CD28. RG-6333 specifically recognizes and binds to the CD19 antigen on the surface of B-cell malignancies to locate tumor cells. RG-6333 activates T cells by binding to CD28, overcoming activation barriers to enhance anti-tumor immunity. RG-6333 can be used in the study of relapsed/refractory non-Hodgkin's lymphoma. The recommended isotype control is human IgG1 kappa, isotype control (HY-P99001).
  • HY-P992182
    ANB032
    		Agonist
    ANB032 is a human IgG4 kappa BTLA agonist monoclonal antibody. ANB032 inhibits activated T cell proliferation and reduces secretion of inflammatory cytokines. ANB032 can be used for the research of atopic dermatitis[1].